Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular, announced today that it will host a Key Opinion Leader (KOL) event for institutional investors and research analysts on June 27, 2017, in New York, NY, focused around discussing the Phase IIa results in hypertension and the upcoming clinical trial in the United States.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2017/05/QGC_PR_KOL-DAY-US_20170523_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]